MX361230B - Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. - Google Patents

Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.

Info

Publication number
MX361230B
MX361230B MX2013008606A MX2013008606A MX361230B MX 361230 B MX361230 B MX 361230B MX 2013008606 A MX2013008606 A MX 2013008606A MX 2013008606 A MX2013008606 A MX 2013008606A MX 361230 B MX361230 B MX 361230B
Authority
MX
Mexico
Prior art keywords
polypeptide
cyaa
immune responses
induce
therapeutic
Prior art date
Application number
MX2013008606A
Other languages
English (en)
Other versions
MX2013008606A (es
Inventor
Esquerré Michael
Momot Marie
Goubier Anne
Misseri Yolande
Original Assignee
Genticel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genticel filed Critical Genticel
Publication of MX2013008606A publication Critical patent/MX2013008606A/es
Publication of MX361230B publication Critical patent/MX361230B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición que comprende un primer grupo de epítopes y un segundo grupo de epítopes, para usarse en el tratamiento inmunoterapéutico de una primera condición patológica y profilaxis de una segunda condición patológica en un huésped mamífero, en donde los grupos de epítopes son de la proteína E6 o de la proteína E7 de un tipo de HPV oncogénico seleccionado del grupo que consiste en HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 Y HPV58, en donde el primer grupo de epítopes está contenido en un polipéptido y el segundo grupo de epítopes está contenido en el mismo polipéptido y dicho polipéptido es llevado por un vector o en donde el primer grupo de epítopes está contenido en un polipéptido diferente y dichos polipéptidos son llevados por el mismo vector o son llevados por vectores separados, y en donde el(los) vectores(es) es(son) una proteína CyaA, o un fragmento de la misma, en donde dicho primer grupo de epítopes no es suficiente para obtener profilaxis contra la segunda condición patológica, en donde el primer grupo de epítopes produce un respuesta inmune de células T contra el primer grupo de epítopes después de administrar dicha composición proporcionando así un tratamiento inmunoterapéutico contra dicha primera condición patológica asociada con dicho primer grupo de epítopes, y en donde, después de administrar dicha composición, el segundo grupo de epítopes produce una respuesta inmune de memoria de células T contra el segundo grupo de epítopes después de administrar dicha composicón, proporcionando así profilaxis contra dicha segunda condición patológica asociada con dicho segundo grupo de epítope.
MX2013008606A 2011-01-24 2012-01-24 Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. MX361230B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305069A EP2478915A1 (en) 2011-01-24 2011-01-24 CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
PCT/EP2012/051027 WO2012101112A1 (en) 2011-01-24 2012-01-24 Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses

Publications (2)

Publication Number Publication Date
MX2013008606A MX2013008606A (es) 2013-12-09
MX361230B true MX361230B (es) 2018-11-30

Family

ID=43971828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008606A MX361230B (es) 2011-01-24 2012-01-24 Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.

Country Status (12)

Country Link
US (1) US9902947B2 (es)
EP (2) EP2478915A1 (es)
JP (2) JP6014604B2 (es)
KR (1) KR101975610B1 (es)
CN (1) CN103476424A (es)
AU (1) AU2012210612B2 (es)
BR (1) BR112013018742A2 (es)
CA (1) CA2825470A1 (es)
ES (1) ES2748381T3 (es)
MX (1) MX361230B (es)
RU (1) RU2668795C2 (es)
WO (1) WO2012101112A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
US10313363B2 (en) * 2015-11-24 2019-06-04 Bank Of America Corporation Proactive intrusion protection system
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290950T3 (es) 1992-04-21 2008-02-16 Institut Pasteur Mutantes recombinantes para inducir respuestas inmunitarias especificas.
EP1188446B1 (en) 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
DE602004024440D1 (de) 2003-11-21 2010-01-14 Pasteur Institut Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
ATE372784T1 (de) * 2004-03-18 2007-09-15 Pasteur Institut Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
EP2061505B9 (en) * 2006-09-01 2013-04-03 Genticel Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
EP2134359A4 (en) * 2007-02-23 2010-06-16 Penn State Res Found USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR

Also Published As

Publication number Publication date
AU2012210612A1 (en) 2013-05-02
MX2013008606A (es) 2013-12-09
EP2478915A1 (en) 2012-07-25
CN103476424A (zh) 2013-12-25
JP2016208979A (ja) 2016-12-15
RU2668795C2 (ru) 2018-10-02
AU2012210612B2 (en) 2016-07-14
US9902947B2 (en) 2018-02-27
BR112013018742A2 (pt) 2017-11-14
KR20140034147A (ko) 2014-03-19
EP2667890B1 (en) 2019-07-03
WO2012101112A1 (en) 2012-08-02
RU2013136148A (ru) 2015-03-10
US20140037670A1 (en) 2014-02-06
EP2667890A1 (en) 2013-12-04
KR101975610B1 (ko) 2019-05-07
CA2825470A1 (en) 2012-08-02
JP6014604B2 (ja) 2016-10-26
ES2748381T3 (es) 2020-03-16
JP2014506562A (ja) 2014-03-17

Similar Documents

Publication Publication Date Title
MX361230B (es) Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
MX354717B (es) Moleculas de union novedosas con actividad antitumoral.
WO2014151960A3 (en) Methods for controlling t cell proliferation
MX2020011781A (es) Formulacion arn para inmunoterapia.
MX2021003370A (es) Estado de ayuno como tratamiento dietetico de la diabetes.
NZ627078A (en) Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
EP4218810A3 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
WO2012050874A3 (en) Targeting heme for the treatment of immune mediated inflammatory diseases
WO2013188627A3 (en) Cationic lipid vaccine compositions and methods of use
WO2017096327A3 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors
IN2014CN04071A (es)
BR112014019328A8 (pt) Perfil de fenótipo de células progenitoras retinais humanas
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
WO2016023898A3 (en) Intracellular antigen binding
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction

Legal Events

Date Code Title Description
FG Grant or registration